What drugs does Ipsen make?
Onivyde® is a registered trademark of Ipsen Biopharm Limited. Somatuline® Depot is a registered trademark of Ipsen Pharma S.A. Dysport® is a registered trademark of Ipsen Biopharm Limited.
What is Ipsen known for?
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience.
What kind of company is Ipsen?
French pharmaceutical company
Ipsen is a French pharmaceutical company headquartered in Paris, France. It is specialized in oncology, neuroscience and rare diseases. It is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). Ipsen S.A.
Is Ipsen biotech company?
Ipsen Pharma Biotech manufactures pharmaceutical products. The company offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. Ipsen Pharma Biotech serves patients worldwide.
Is Ipsen a big company?
With total sales close to €2.576 billion in 2019, Ipsen markets more than 20 drugs in over 115 countries with a direct commercial presence in 37 countries. Our R&D focus is on developing innovative medicines that address unmet patient needs in the areas of oncology, neuroscience and rare diseases.
Where is Ipsen Pharma located?
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts. group, announced it will establish its North American headquarters in Cambridge, Massachusetts.
Where is Ipsen located?
Where is Ipsen located in the US?
Cambridge, Massachusetts
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts. group, announced it will establish its North American headquarters in Cambridge, Massachusetts.
Where is Ipsen headquartered?
Paris, FranceIpsen / Headquarters
How many employees does Ipsen have?
How many employees does Ipsen have? Ipsen has 5,700 employees.
What is oncology Ipsen?
Oncology. Ipsen entered the field of oncology in 1986 and our portfolio now includes treatments for neuroendocrine tumors (NETs), prostate cancer, and cancers of the bladder, kidney, pancreas and breast. Focusing on these selected cancers, we aim to provide fully integrated patient care.
What is Ipsen doing for You?
Our mission is to improve patients’ lives. Access our development and commercialization teams. We take bold steps to translate your science and innovations into solutions that make a difference for patients in need. What’s happening now? You are about to leave Ipsen.com/us.
What happens when a physician requests Ipsen product for early access?
If the request for Early Access is approved by Ipsen, the Physician must collect and complete all necessary documents to comply with appropriate rules and regulations – as quickly as possible. Once collected, Ipsen will send the Physician the requested Ipsen Product for Early Access to treat their patient.
How long has Ipsen been working on GI disorders?
We have over 45 years of experience in gastrointestinal (GI) disorders as well as expertise in cognitive disorders, pain, cough and cold therapeutic areas. At Ipsen, our research decisions are guided by patient outcomes.